# OnCo record follicular-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/follicular-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "follicular-lymphoma" ;
  schema:name "Follicular lymphoma"@en ;
  schema:description "Follicular lymphoma is the most common slow-growing lymphoma, defined in about 85% of cases by a BCL2 translocation. Most people live with it for decades, treated only when it causes problems; it can be controlled repeatedly with anti-CD20 antibodies, chemotherapy, bispecifics or CAR-T but rarely cured, and a small share transform into an aggressive lymphoma each year."@en ;
  schema:url <https://onco.cc/cancers/follicular-lymphoma/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Follicular_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q123251> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480>, <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/>, <https://lymphoma-action.org.uk/information-and-support/support-you/helpline-services>, <https://lymphoma-action.org.uk/information-and-support/tests-scans-and-lymphoma-staging/questions-ask-your-medical-team-about-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/follow-after-lymphoma-treatment>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/infections-risk-and-prevention>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/neutropenia-low-neutrophils>, <https://lymphoma-action.org.uk/information-and-support/side-effects-lymphoma-and-treatment/cancer-related-fatigue>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/day-day-living/lymphoma-work-and-you>, <https://www.maggies.org/support-and-information/>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/non-hodgkin-lymphoma/follicular-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/lymphoma-treatment/active-monitoring-watch-and-wait>, <https://lymphoma-action.org.uk/information-and-support/types-lymphoma/transformation-lymphoma>, <https://lymphoma-action.org.uk/information-and-support/living-and-beyond-lymphoma/emotional-impact-living-lymphoma>, <https://doi.org/10.1016/S1470-2045(14)70027-0>, <https://www.macmillan.org.uk/cancer-information-and-support/lymphoma/non-hodgkin-lymphoma> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/collections/lymphoma-research-foundation/>, <https://onco.cc/cancers/marginal-zone-lymphoma/>, <https://onco.cc/cancers/waldenstrom/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/biomarkers/bcl2-rearrangement/>, <https://onco.cc/biomarkers/ezh2-y646-mutation/>, <https://onco.cc/biomarkers/double-hit-rearrangement/>, <https://onco.cc/biomarkers/ig-tcr-clonality/>, <https://onco.cc/roadmaps/lymphoma-roadmap/>, <https://onco.cc/ideas/lymphoma-ev-fixed-duration-chemotherapy-free-first-line/>, <https://onco.cc/ideas/lymphoma-ev-ctdna-instead-of-the-interim-scan/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/radioimmunotherapy/>, <https://onco.cc/technologies/palliative-care/>, <https://onco.cc/technologies/psycho-oncology/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/survivorship-care-plan/>, <https://onco.cc/technologies/fertility-preservation/>, <https://onco.cc/technologies/financial-navigation/>, <https://onco.cc/technologies/cbt-fatigue-distress/>, <https://onco.cc/technologies/exercise-during-chemotherapy/>, <https://onco.cc/technologies/multidisciplinary-tumour-board/>, <https://onco.cc/technologies/oncology-nutrition/>, <https://onco.cc/technologies/prehabilitation/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/cytogenetics-fish/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd3/>, <https://onco.cc/targets/bcl2/>, <https://onco.cc/targets/ezh2/>, <https://onco.cc/targets/btk/>, <https://onco.cc/targets/crebbp/>, <https://onco.cc/targets/ep300/>, <https://onco.cc/targets/kmt2d/>, <https://onco.cc/targets/cd79b/>, <https://onco.cc/targets/myc-gene/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/ibritumomab-tiuxetan/>, <https://onco.cc/drugs/tafasitamab/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/genmab/>, <https://onco.cc/companies/abbvie/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/beone/>, <https://onco.cc/companies/regeneron/>, <https://onco.cc/companies/haihe-biopharma/> ;
  onco:pathways <https://onco.cc/pathways/apoptosis-bcl2/>, <https://onco.cc/pathways/germinal-centre-reaction/>, <https://onco.cc/pathways/epigenetic-reprogramming/> ;
  onco:terms <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/lymphoma-tx-pod24/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-uk-access/>, <https://onco.cc/terms/cancer-related-fatigue/>, <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/febrile-neutropenia/>, <https://onco.cc/terms/neutropenia/>, <https://onco.cc/terms/financial-toxicity/>, <https://onco.cc/terms/central-venous-access/>, <https://onco.cc/terms/hypogammaglobulinaemia/>, <https://onco.cc/terms/performance-status/>, <https://onco.cc/terms/quality-of-life/>, <https://onco.cc/terms/lymphoma-decision-watch-and-wait/>, <https://onco.cc/terms/lymphoma-decision-trial/>, <https://onco.cc/terms/lymphoma-decision-fertility-timing/>, <https://onco.cc/terms/lymphoma-living-indolent-lymphoma/>, <https://onco.cc/terms/lymphoma-living-scanxiety-and-surveillance/>, <https://onco.cc/terms/lymphoma-living-fatigue/>, <https://onco.cc/terms/lymphoma-living-infection-years-after/>, <https://onco.cc/terms/lymphoma-living-vaccinations/>, <https://onco.cc/terms/lymphoma-living-returning-to-work/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/terms/deauville/>, <https://onco.cc/terms/lymphoma-bio-germinal-centre/>, <https://onco.cc/terms/lymphoma-bio-transformation/>, <https://onco.cc/terms/lymphoma-bio-antigen-escape/> ;
  onco:trials <https://onco.cc/trials/nct07634471/>, <https://onco.cc/trials/nct07562022/>, <https://onco.cc/trials/nct06097364/>, <https://onco.cc/trials/nct04712097/>, <https://onco.cc/trials/nct06549595/>, <https://onco.cc/trials/nct06149286/>, <https://onco.cc/trials/nct06191744/>, <https://onco.cc/trials/nct06911502/>, <https://onco.cc/trials/nct04224493/>, <https://onco.cc/trials/nct01804686/>, <https://onco.cc/trials/nct04680052/>, <https://onco.cc/trials/nct06091254/>, <https://onco.cc/trials/nct05100862/>, <https://onco.cc/trials/nct05888493/>, <https://onco.cc/trials/nct05409066/>, <https://onco.cc/trials/nct05371093/>, <https://onco.cc/trials/augment/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/trials/relevance/>, <https://onco.cc/trials/prima-follicular/>, <https://onco.cc/trials/trog-99-03/>, <https://onco.cc/trials/elara/>, <https://onco.cc/trials/rosewood/>, <https://onco.cc/trials/fortplus/>, <https://onco.cc/trials/mosun-lbt-fl/> ;
  onco:journals <https://onco.cc/journals/hematological-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/golcadomide/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/sctb35/>, <https://onco.cc/drugs/xnw5004/>, <https://onco.cc/drugs/tc011/>, <https://onco.cc/drugs/crc01/>, <https://onco.cc/drugs/ctx112/> ;
  onco:standardOfCare <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/fort/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/active-surveillance/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/trials/relevance/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/key-papers/paper-fort-4gy-vs-24gy-indolent-lymphoma-hoskin-lancet-oncol-2014/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/lymphoma-tx-watch-and-wait/>, <https://onco.cc/terms/watchful-waiting/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/trials/gallium/>, <https://onco.cc/trials/relevance/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/terms/lymphoma-tx-maintenance/>, <https://onco.cc/key-papers/paper-rummel-lancet/>, <https://onco.cc/key-papers/paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017/>, <https://onco.cc/key-papers/paper-relevance-rituximab-lenalidomide-follicular-lymphoma-morschhauser-nejm-2018/>, <https://onco.cc/terms/lymphoma-tx-pod24/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/terms/flipi/>, <https://onco.cc/trials/augment/>, <https://onco.cc/trials/zuma-5/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/odronextamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/bendamustine/>, <https://onco.cc/drugs/tazemetostat/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/tafasitamab/>, <https://onco.cc/drugs/zanubrutinib/>, <https://onco.cc/technologies/radioimmunotherapy/>, <https://onco.cc/terms/lymphoma-tx-bispecific-step-up/>, <https://onco.cc/terms/lymphoma-tx-radiotherapy/>, <https://onco.cc/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/>, <https://onco.cc/terms/r-chop/>, <https://onco.cc/trials/polarix/>, <https://onco.cc/drugs/polatuzumab-vedotin/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/lisocabtagene-maraleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/terms/lymphoma-tx-car-t-pathway/>, <https://onco.cc/terms/lymphoma-tx-pod24/> .